<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="383">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679584</url>
  </required_header>
  <id_info>
    <org_study_id>COVIDOM-Protokoll_V01F_2020-10</org_study_id>
    <secondary_id>DRKS00023742</secondary_id>
    <nct_id>NCT04679584</nct_id>
  </id_info>
  <brief_title>COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life</brief_title>
  <acronym>NAPKON-POP</acronym>
  <official_title>COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life (NAPKON-POP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is a novel disease caused by SARS-CoV-2 that primarily affects the lungs but also&#xD;
      various other organs of the body already in early stages of the disease. Due to the multiple&#xD;
      organ involvements in the acute phase, it is conceivable that - in a significant proportion&#xD;
      of patients - longterm sequels in various organ systems might occur, thereby impacting the&#xD;
      individual's health status and quality of life; and posing a relevant burden to the resources&#xD;
      of the health care system&#xD;
&#xD;
      Assessment of SARS-CoV-2-longterm morbidity and sequels on the population level:&#xD;
&#xD;
      In order to identify and treat these sequels in a timely fashion and to get a sense of the&#xD;
      prevalence of such SARS-CoV-2 sequels on the population level, it is important to collect&#xD;
      follow-up data and to comprehensively re-examine a population-representative sample of&#xD;
      SARS-CoV-2 infected individuals.&#xD;
&#xD;
      Within the COVIDOM study we will conduct deep clinical and biochemical phenotyping in&#xD;
      population-representative samples in Germany. This will allow novel insights into disease&#xD;
      pathogenesis and chronicity of virus infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      COVID-19 is a novel disease caused by SARS-CoV-2. Severity of infection in the acute phase&#xD;
      ranges from asymptomatic to critically ill and fatal courses of the disease. Besides the&#xD;
      acute respiratory distress syndrome (ARDS), also thromboembolic events and acute damages of&#xD;
      other organs are contributing to severe and critical courses of the disease in the acute&#xD;
      phase of the infection.&#xD;
&#xD;
      It is, however, largely unknown whether and to what extent different organs are affected in&#xD;
      individuals with milder courses of the disease.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        1. Across all severity stages in the acute phase, SARS-CoV-2 infection causes longterm&#xD;
           damages in various organ systems in a significant proportion of patients.&#xD;
&#xD;
        2. Beyond the damages directly caused by the infection, also the behavioral changes&#xD;
           implemented to reduce the spread of the virus might impact an individual's health status&#xD;
           and quality of life.&#xD;
&#xD;
        3. The infection itself and the pandemic in general results in increased use of health care&#xD;
           resources.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      SARS-CoV-2 infected individuals in defined geographic regions will be contacted through the&#xD;
      responsible health authorities and will be informed about the study and invited to&#xD;
      participate. These individuals will presumably represent all severity grades in the initial&#xD;
      phase of the infection (asymptomatic, uncomplicated, complicated, critical course of disease)&#xD;
      and each of them will be offered a detailed clinical examination program that Includes&#xD;
      structural and functional assessment of various organ systems (lungs, cardiovascular, CNS&#xD;
      including smell/tase, liver), a comprehensive medical history, as well as psychological and&#xD;
      psychiatric assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Longterm morbidities and sequels of SARS-CoV-2 infections in the general population</measure>
    <time_frame>Preliminary results in 03/2021</time_frame>
    <description>Chronic organ impairments, especially of the lungs, heart, liver, central nervous system, smell and taste or psychological well-being bases on functional assessments (i.e. lung function including forced spirometry, bodyplethysmography, diffusing capacity for CO, FeNO, echocardiography, testing of smell and taste, neurological assessment, psychological assessment) and biomarker studies (blood, nasopharyngeal swabs, urin, stool)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longterm quality of life of SARS-CoV-2 infected individuals recruited from the general population</measure>
    <time_frame>Preliminary results in 03/2021</time_frame>
    <description>Longitudinal assessment of general and health-related quality of Life, as well as health status in SARS-CoV-2 infected individuals of different severity grades</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longterm health care utilization of SARS-CoV-2 infected individuals recruited from the general population</measure>
    <time_frame>Preliminary results in 03/2021</time_frame>
    <description>Longitudinal assessment of health-care utilization based on insurance data in SARS-CoV-2 infected individuals of different severity grades</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)</arm_group_label>
    <description>Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, SUEP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)</arm_group_label>
    <description>Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (POP, SUEP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intersectoral Platform (SUEP) of the National Pandemic Cohort Network (NAPKON)</arm_group_label>
    <description>Streamlined sampling of biomaterials and core data elements (GErman Corona COnsensu data set, GECCO) with other NAPKON study platforms (HAP, POP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings</intervention_name>
    <description>Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care</description>
    <arm_group_label>High-Resolution Platform (HAP) of the National Pandemic Cohort Network (NAPKON)</arm_group_label>
    <arm_group_label>Intersectoral Platform (SUEP) of the National Pandemic Cohort Network (NAPKON)</arm_group_label>
    <arm_group_label>Populationbased Platform (POP) of the National Pandemic Cohort Network (NAPKON)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        SARS-CoV-2 infected individuals in defined geographic regions will be contacted through the&#xD;
        responsible health authorities and will be informed about the study and invited to&#xD;
        participate. These individuals will presumably represent all severity grades in the initial&#xD;
        phase of the infection (asymptomatic, uncomplicated, complicated, critical course of&#xD;
        disease) and each of them will be offered a detailed clinical examination program that&#xD;
        Includes structural and functional assessment of various organ systems (lungs,&#xD;
        cardiovascular, CNS including smell/tase, liver), a comprehensive medical history, as well&#xD;
        as psychological and psychiatric assessments.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PCR-confirmed SARS-CoV-2 infection&#xD;
&#xD;
          -  living in one of the target areas&#xD;
&#xD;
          -  age at least 18 years&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute SARS-CoV-2 infection or reinfection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Schreiber, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Internal Medicine Department I, UKSH Kiel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Schreiber, Prof. Dr.</last_name>
    <phone>0049 (0)431 500 22201</phone>
    <email>s.schreiber@mucosa.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Bahmer, Prof. Dr.</last_name>
    <phone>0049 (0) 431 500 62629</phone>
    <email>thomas.bahmer@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Wuerzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bavaria</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Heuschmann, Prof. Dr.</last_name>
      <phone>0931 201 470308</phone>
      <email>E_Heuschma_P@ukw.de</email>
    </contact>
    <contact_backup>
      <last_name>Jens-Peter Reese, Prof. Dr.</last_name>
      <phone>0931 201 470308</phone>
    </contact_backup>
    <investigator>
      <last_name>Stefan Stark, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Hermes, Prof. Dr.</last_name>
      <phone>0049 (0) 431 500 30240</phone>
      <email>info@covidom.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Bahmer, Prof. Dr.</last_name>
      <phone>0049 (0) 431 500 62629</phone>
      <email>thomas.bahmer@uksh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Schreiber, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Bahmer, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lieb Wolfgang, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krawczak Michael, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Keil, Prof. Dr.</last_name>
      <phone>0049 (0)30 450 529 902</phone>
      <email>thomas.keil@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Lilian Krist, Dr.</last_name>
      <phone>0049 (0)30 450 529 902</phone>
      <email>lilian.krist@charite.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.covidom.de</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.napkon.de</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>COVID</keyword>
  <keyword>Corona</keyword>
  <keyword>longterm morbidity</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>longterm consequences</keyword>
  <keyword>Chronic impairment</keyword>
  <keyword>Chronic dysfunction</keyword>
  <keyword>Chronicity</keyword>
  <keyword>Sequels</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Please see use and access conditions according to www.napkon.de</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

